VITRUVIAE
VITRUVIAE develops cancer-targeted immunotherapies that recognize glycan and lipid signatures present on tumor cells and cancer stem cells but absent on healthy cells. The company’s proprietary dual sugar–lipid targeting platform is engineered into multiple immunotherapy formats (T‑cell engagers, CAR T cells, NK cell engagers, and radio theranostics) and is being advanced in preclinical programs for hematologic malignancies (including pediatric and adult AML) and solid tumors.
Industries
Nr. of Employees
small (1-50)
Patents
Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
US-11197910-B1
View Details
Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
US-11197910-B1
View DetailsProducts
VTRU200
Preclinical trispecific T‑cell engager program prioritized for acute myeloid leukemia (AML); reported to bind and eliminate AML tumor cells and leukemic stem cells in animal models.
VTRU100
Fc‑fusion protein program described as targeting cytomegalovirus (CMV).
VTRU300
Trispecific NK cell engager program aimed at solid tumors.
VCAR300
Chimeric antigen receptor (CAR) T cell program for solid tumors using glycan/lipid-targeting recognition.
VRAD600
Radio theranostic program combining radioactive delivery with targeting moieties for diagnostic and therapeutic applications in solid tumors.
VTRU200
Preclinical trispecific T‑cell engager program prioritized for acute myeloid leukemia (AML); reported to bind and eliminate AML tumor cells and leukemic stem cells in animal models.
VTRU100
Fc‑fusion protein program described as targeting cytomegalovirus (CMV).
VTRU300
Trispecific NK cell engager program aimed at solid tumors.
VCAR300
Chimeric antigen receptor (CAR) T cell program for solid tumors using glycan/lipid-targeting recognition.
VRAD600
Radio theranostic program combining radioactive delivery with targeting moieties for diagnostic and therapeutic applications in solid tumors.
Expertise Areas
- Glycan and lipid-targeted immunotherapy
- CAR T and engineered cell therapy development
- Bispecific/trispecific T‑cell and NK cell engager design
- Preclinical in vivo efficacy and safety testing
Key Technologies
- Glycan and lipid antigen targeting
- Chimeric antigen receptor (CAR) T cell therapy
- T‑cell engager (bispecific/trispecific) platforms
- NK cell engager platforms
News & Updates
Preclinical in vivo results demonstrating efficacy of immunotherapy candidates against leukemias and solid tumors; abstract listed as ASCO Abstract #246805.
Presentation and publication of preclinical CAR T cell data targeting a cancer-associated glycan and lipid signature in pancreatic cancer (AACR 2025; abstract LB028).
Oral presentation describing preclinical results for a T‑cell engager in hematologic malignancies with a reported safety profile.
Investigator award recognizing work on the company’s immunotherapy platform for pediatric AML; award supports continued research.
Company received CSIT grants to advance targeted biotherapeutics for maternal and infant health.
Academic collaborator received a grant from a pediatric cancer foundation to study the company’s trispecific immunotherapy platform for pediatric AML.
Preclinical in vivo results demonstrating efficacy of immunotherapy candidates against leukemias and solid tumors; abstract listed as ASCO Abstract #246805.
Presentation and publication of preclinical CAR T cell data targeting a cancer-associated glycan and lipid signature in pancreatic cancer (AACR 2025; abstract LB028).
Oral presentation describing preclinical results for a T‑cell engager in hematologic malignancies with a reported safety profile.
Investigator award recognizing work on the company’s immunotherapy platform for pediatric AML; award supports continued research.
Company received CSIT grants to advance targeted biotherapeutics for maternal and infant health.
Academic collaborator received a grant from a pediatric cancer foundation to study the company’s trispecific immunotherapy platform for pediatric AML.